61072-56-8

Basic information

• Product Name: 4-CHLORO-2-FLUOROBENZALDEHYDE
• Synonyms: 4-Chloro-2-fluorobenzaldehyde,99%;3-Fluoro-4-formylchlorobenzene;2-fluoro-4-chlorobenzene Methylal;4-Chloro-2-fluorobenzaldehyde, 99% 5GR;4-CHLORO-2-FLUOROBENZALDEHYDE;2-FLUORO-4-CHLOROBENZALDEHYDE;TIMTEC-BB SBB003985;4-Chloro-2-Fluorobenzaldehyde 2-Fluoro-4-Chlorobenzaldehyde
• CAS NO: 61072-56-8
• Molecular Formula: C₇H₄ClFO
• Molecular Weight: 158.56
• EINECS: -0
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Benzaldehyde;Adehydes, Acetals & Ketones;Chlorine Compounds;Fluorine Compounds
• Mol File: 61072-56-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 58-61 °C
• Boiling Point: 118-120 C
• Flash Point: 80.69 °C
• Appearance: White to yellow-beigeor/Crystals or Powder
• Density: 1.3310 (estimate)
• Vapor Pressure: 0.199mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: Refrigerator
• Water Solubility: Insoluble
• Sensitive: Air Sensitive
• BRN: 3537705
• CAS DataBase Reference: 4-CHLORO-2-FLUOROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2-FLUOROBENZALDEHYDE(61072-56-8)
• EPA Substance Registry System: 4-CHLORO-2-FLUOROBENZALDEHYDE(61072-56-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22-22
• Safety Statements: 37/39-26-36-37
• TSCA: T
• HazardClass: IRRITANT, AIR SENSITIVE
• Hazardous Substances Data: 61072-56-8(Hazardous Substances Data)

Usage

Chemical Properties

light yellow solid or liquids

Uses

4-Chloro-2-fluorobenzaldehyde is used as pharmaceutical intermediates.

InChI:InChI=1/C7H4ClFO/c8-6-2-1-5(4-10)7(9)3-6/h1-4H

Upstream product

• 874-42-0 2,4-dichlorobenzaldeyhde 
• 446-30-0 4-chloro-2-fluorobenzoic acid 
• 56456-49-6 (4-chloro-2-fluorophenyl)methanol 
• 452-66-4 5-chloro-2-fluorotoluene 
• 452-75-5 4-chloro-2-fluorotoluene 
• 71916-82-0 1-(bromomethyl)-4-chloro-2-fluorobenzene 

Downstream Products

• 1008562-79-5 4-chloro-2-(2-fluoro-6-methoxy-phenoxy)-benzaldehyde 
• 190130-64-4 4-chloro-2-fluorobenzaldehyde (N-methyl)hydrazone 
• 1042671-41-9 C₁₂H₁₀ClFO₂ 
• 1042671-44-2 C₁₀H₉ClFNO₂ 
• 1084712-41-3 3-(p-chlorophenyl)-5-p-tolyl-4-(2-fluoro-4-chlorobenzylideneamino)-4H-1,2,4-triazole 
• 1122589-16-5 (E)-3-(4-chlorophenyl)-5-(pyridin-4-yl)-4-(2-fluoro-4-chlorobenzylidenamino)-4H-1,2,4-triazole 
• 1202774-93-3 (4-Chloro-2-fluorophenyl)(cyclopropyl)methanol 
• 1360060-33-8 3-[(E)-2-(4-chloro-2-fluorophenyl)vinyl]-4-methoxybenzamide 
• 1287708-74-0 N-{4-[3-(4-chloro-2-fluorophenyl)-2-(E)-propenoyl]phenyloxyacetyl}aminodihydroartemisinin 
• 1345888-67-6 N-{4-[3-(4-chloro-2-fluorophenyl)-2-(E)-propenoyl]phenyloxyacetyl}aminodihydroartemisinin 
• 1345888-77-8 C₁₅H₁₀ClFO₂ 
• 885521-34-6 3-bromo-6-chloro-1H-indazole 
• 90987-48-7 8-chloro-10-(4-chlorophenyl)-2H,3H,4H,10H-pyrimido[4,5-b]quinoline-2,4-dione 
• 1443042-21-4 2-(4-chloro-2-fluorobenzylidene)-1-(5-bromo-2-chloropyrimidin-4-yl)hydrazine 

Relevant articles and documents

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acc

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Enantioselective syntheses of no-carrier-added (n.c.a.) (S)-4-chloro-2-[18F] fluorophenylalanine and (S) - (α-methyl) -4-chloro-2-[18F]fluorophenylalanine

(S)-4-Chloro-2-fluorophenylalanine and (S)-(α-methyl)-4-chloro-2-fluorophenylalanine were synthesized and labeled with no carrier added (n.c.a.) fluorine-18 through a radiochemical synthesis relying on the highly enantioselective reaction between 4-chloro-2-[18F]fluorobenzyl iodide and the lithium enolate of (2S)-1-(tert-butyloxycarbonyl)-2-(tert-butyl)-3-methyl-1,3-imidazolidine-4-one for (S)-4-chloro-2-[18F]fluorophenylalanine and (2S,5S)-1-(tert-butyloxycarbonyl)-2-(tert-butyl)-3,5-dimethyl-1,3-imidazolidine-4-one for (S) - (α-methyl)-4-chloro-2-[18F] fluorophenylalanine. Quantities of about 20-25 mCi were obtained at the end of synthesis, ready for injection after hydrolysis and high performance liquid chromatography (HPLC) purification, with a radiochemical yield of 17%-20% corrected to the end of bombardment after a total synthesis time of 90-105 min from [18F]fluoride. The enantiomeric excesses were shown to be 97% or more for both molecules without chiral separation and the radiochemical and chemical purities were 98% or better.